Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ODTX

Odyssey Therapeutics Inc

18.13

Aug 03 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Today, 7:06 AMOdyssey Therapeutics says $433.1M cash funds operations into 2H 2028, reaffirms key OD-001 and OD-002 2H 2026 milestones

Peers: ARVN BBOT XNCR CGEM CTMX JANX KURA ALLO RVMD ROIV

| Held by: VTI VXF SCHA SCHB VTWO MSSM VTWG VTWV VTHR

Scroll to Statements

Index	-
Market Cap	870.81M
Enterprise Value	1.42B
Income	-
Sales	-
Book/sh	-10.90
Cash/sh	3.66
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	May 08, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	4.95
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.33
Current Ratio	8.33
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-4.19
EPS next Q	-0.94
EPS this Y	12.07%
EPS next Y	7.61%
EPS next 5Y	5.86%
EPS past 3/5Y	-6.04% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Jun 17 AMC
EPS/Sales Surpr.	-507.99% -

Insider Own	44.12%
Insider Trans	24.59%
Inst Own	9.87%
Inst Trans	17.39%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.56%
SMA50	3.16%
SMA200	3.38%
Trades

Shs Outstand	48.03M
Shs Float	26.84M
Short Float	7.43%
Short Ratio	5.30
Short Interest	1.99M
52W High	20.30 -10.69%
52W Low	15.10 20.07%
Volatility	7.05% 8.14%
ATR (14)	1.35
RSI (14)	52.01
Beta	-
Rel Volume	0.00
Avg Volume	375.93K
Volume	0

Perf Week	-4.73%
Perf Month	7.92%
Perf Quarter	-
Perf Half Y	-
Perf YTD	-9.35%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	32.00
Prev Close	18.13
Price	18.13
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-26	Initiated	Wedbush	Outperform	$30
Jun-02-26	Initiated	TD Cowen	Buy
Jun-02-26	Initiated	Oppenheimer	Outperform	$40
Jun-02-26	Initiated	JP Morgan	Overweight	$26
Jun-02-26	Initiated	Cantor Fitzgerald	Overweight

Today 07:00AM	Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-18-26 12:56PM	Kardigan rises in Nasdaq debut after upsized $400 million IPO (Reuters)
Jun-17-26 04:51PM	Odyssey Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:15PM	Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-26 08:31AM	Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip (GuruFocus.com) +6.27%

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.

FounderDr. Gary D. Glick Ph.D.

Chief Financial OfficerMr. Jason Haas M.B.A.

Senior Vice President of Strategy & Business DevelopmentMr. Collin Todd

Ph.D.Prof. Eicke Latz M.D.

Scientific Co-FounderDr. Kim Lewis Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TPG GP A, LLC	Former 10% Owner	May 11 '26	Buy	18.00	1,388,889	25,000,002	3,690,146	May 13 05:10 PM
Dimension Capital II, L.P.	Director	May 08 '26	Buy	18.00	1,111,111	19,999,998	3,333,516	May 12 05:37 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Buy	18.00	555,555	9,999,990	1,831,383	May 11 09:11 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Sale	18.00	1,780	32,040	440,981	May 11 09:11 PM
LEIDEN JEFFREY M	Director	May 08 '26	Buy	20.00	5,000	100,000	270,198	May 11 08:35 PM
Haas Jason	Chief Financial Officer	May 08 '26	Buy	20.00	1,000	20,000	62,908	May 11 08:32 PM
Li Nan (LN)	Director	May 11 '26	Buy	18.00	1,111,111	19,999,998	3,333,516	May 11 08:30 PM
Chu Shelley	Director	May 11 '26	Buy	18.00	11,111	199,998	11,111	May 11 08:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ODTX

Odyssey Therapeutics Inc

Upgrade your Finviz experience